Baricitinib: From Rheumatoid Arthritis to COVID-19

April 2021 in “ Journal of clinical pharmacology ”

Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, Bahareh Mohebbi, Mohammad Hossein Nicknam

baricitinib JAK1/2 inhibitor alopecia areata hair regrowth

TLDR Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Baricitinib, a JAK1/2 inhibitor initially approved for rheumatoid arthritis, has shown efficacy in treating various inflammatory and autoimmune diseases, including COVID-19, systemic lupus erythematosus, psoriasis, atopic dermatitis, and alopecia areata. Clinical trials have demonstrated significant improvements in disease activity and symptoms across these conditions, with notable hair regrowth in alopecia areata patients. However, its use is associated with adverse effects such as infections, liver enzyme dysregulation, and potential malignancies, necessitating careful monitoring and further research to fully understand its safety profile and optimize treatment regimens.

View this study on accp1.onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Treatment of Severe Alopecia Areata with Baricitinib

25 citations, October 2019 in “JAAD Case Reports”

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations, February 2015 in “EBioMedicine”

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

Similar Research

5 / 397 results

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations, October 2019 in “Frontiers in Immunology”

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

9 citations, January 2023 in “Dermatology and therapy”

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

$Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib$

research Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib

3 citations, June 2023 in “Journal of cosmetic dermatology”

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers

70 citations, April 2016 in “Experimental Dermatology”

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

research Janus Kinase Inhibitors for Alopecia Areata

7 citations, August 2023 in “Journal of the American Academy of Dermatology”

JAK inhibitors offer new hope for treating severe alopecia areata.

Baricitinib: From Rheumatoid Arthritis to COVID-19

Research cited in this study

research Treatment of Severe Alopecia Areata with Baricitinib

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

Related Community Posts Join

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

community Anyone heard of or have experience using baricitinib?

community Olumiant active ingredient Baricitinib

community Lilly to seek first approval of an autoimmune drug for hair loss

community Does a minoxidil tester exist? To test if whatever you get is actually minoxidil or some fake?